Dr. Foss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
Cleveland, OH 44195Phone+1 800-223-2273
Education & Training
University of Chicago Medical CenterFellowship, Clinical Pharmacology, 1990 - 1991- University of ChicagoResidency, Anesthesiology, 1986 - 1989
Oregon Health Science University HospitalInternship, Transitional Year, 1985 - 1986
The Warren Alpert Medical School of Brown UniversityClass of 1985
Certifications & Licensure
OH State Medical License 2006 - 2027
IL State Medical License 1986 - 2017
PA State Medical License 2004 - 2006
MI State Medical License 1994 - 2004- American Board of Anesthesiology Anesthesiology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Safety and Tolerability of NTRX-07 in Healthy Volunteers Start of enrollment: 2019 Oct 10
Publications & Presentations
PubMed
- 42 citationsDose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs.Joseph F. Foss, Alan S. Bass, Leon I. Goldberg
Journal of Clinical Pharmacology. 1993-08-01 - 18 citationsAmyloid Fibril-Induced Astrocytic Glutamate Transporter Disruption Contributes to Complement C1q-Mediated Microglial Pruning of Glutamatergic Synapses.Jiang Wu, Bihua Bie, Joseph F. Foss, Mohamed Naguib
Molecular Neurobiology. 2020-02-01 - 47 citationsActivation of mGluR1 Mediates C1q-Dependent Microglial Phagocytosis of Glutamatergic Synapses in Alzheimer’s Rodent ModelsBihua Bie, Jiang Wu, Joseph F. Foss, Mohamed Naguib
Molecular Neurobiology. 2019-01-16
Press Mentions
Latest Alzheimer’s Treatment Shows Promise for Your Aging Loved OnesNovember 1st, 2016- Latest Alzheimer’s Treatment Shows Promise for Your Aging Loved OnesNovember 1st, 2016
Cleveland Clinic Researchers Discover New Brain Protein Linked to Alzheimer'sFebruary 10th, 2016
Grant Support
- Development of a novel CB2 agonistAlzheimer’s Drug Discovery Foundation2014–2015
Committees
- Vice chairman, Institutional Review Board Cleveland Clinic 2010 - Present
Research History
- PIClincal Development of NTRX-07 for the treatment of chronic neuropathic pain and neurodegenerative disease.2014 - Present
Professional Memberships
- Member
- Member
- Member
- International Society Anesthesia PharmacologySecretary, BOD
Industry Relationships
- Founder, NeuroTherapia Inc.NeuroTherapia is a Cleveland Clinic spinoff bringing novel compounds based on the work of Dr. Mohamed Naguib to the clinic. NTRX-07 is the lead compound which has shown efficacy in models of neuropathic pain and Alzheimer's disease.2015 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
